Claude设计抗蝎毒蛋白结合物,17个通过结合测试
Anthropic称,其内部研究版Claude在Claude Science环境中与投资研究机构Citrini Research合作,针对来自四个物种的五种蝎毒神经毒素设计微型结合蛋白,在64小时计算阶段生成318484个设计并筛出180个候选,团队又补充31个。Adaptyv Bio与Twist Bioscience对全部211个设计做了结合测试,其中17个达到团队设定的标准,覆盖五种毒素中的四种,表现最强的候选与Cn2毒素结合紧密。多家报道强调,结合并不等于中和毒素;专家对The Verge表示,这批分子是有希望的起点,但远不是药物。Anthropic已公开全部211个设计、预测结构和结合数据。
该实验记录了一个前沿模型在完整蛋白设计流程中协调文献检索、设计工具与供应商制造约束的过程,且全部数据已公开供其他研究者复核。
**Summary:**As part of our work experimenting with how Claude can help accelerate drug discovery, we asked an internal research model to design minibinders (small proteins that attach tightly to a target) against scorpion neurotoxins. Claude worked from our prompt and four follow-ups, which we developed in collaboration with the financial investment research firm Citrini Research. Teams at Adaptyv Bio and Twist Bioscience experimentally tested 211 designs for binding. Of these, 17 met our criteria. We’re releasing all 211 designs and their data as a resource for the field.
In August, we showed how Claude designed protein minibinders after being given a single prompt. A month before we released those results, a team from Citrini Research had approached us with an interesting question: could Claude (and AI drug discovery more generally) enable a group of motivated nonexperts to tackle a genuine problem in human health? Members of our life science research team set out to answer this, first by brainstorming problems with Claude. We landed on asking for Claude’s help designing novel protein binders against scorpion neurotoxins, with the hope that they could one day be used to develop a scorpion antivenom.
#Anthropic#Claude Science#Citrini Research#Adaptyv Bio#Twist Bioscience